Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02831179
Other study ID # VICC GI 14134
Secondary ID NCI-2016-01044
Status Withdrawn
Phase Phase 1
First received July 10, 2016
Last updated September 26, 2017
Start date December 2017
Est. completion date February 2020

Study information

Verified date September 2017
Source Vanderbilt-Ingram Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of veliparib when given together with capecitabine and temozolomide in treating patients with neuroendocrine tumor that has spread to other places in the body and usually cannot be cured or controlled with treatment, has returned after a period of improvement, and cannot be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.


Description:

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of veliparib (ABT-888) in combination with capecitabine and temozolomide in patients with advanced well-differentiated neuroendocrine tumors.

SECONDARY OBJECTIVES:

2. To determine the safety profile of the combination of capecitabine, temozolomide and veliparib in patients with advanced well-differentiated neuroendocrine tumors (NET).

3. To evaluate the antitumor activity of the combination of capecitabine, temozolomide and veliparib in advanced well-differentiated NET patients

4. To determine progression-free survival (PFS) of the combination of capecitabine, temozolomide, and veliparib in advanced well-differentiated NET patients IV. To evaluate the association between pharmacodynamic biomarkers and response in patients with advanced well-differentiated NET patients.

OUTLINE: This is a dose-escalation study of veliparib.

Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 2020
Est. primary completion date February 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pathologically confirmed metastatic unresectable well differentiated (low grade and intermediate grade) neuroendocrine tumors (Ki-67 < 20% and mitotic rate < 2 per 10 high power field) that demonstrate progressive disease (by serial computed tomography [CT] or magnetic resonance imaging [MRI] scans) in past 12 months including

- Carcinoid tumors originating anywhere in the body including the gastrointestinal (GI) tract or bronchial tree or thymus

- Pancreatic neuroendocrine tumors (including functional and non-functional islet cell, insulinomas and glucagonomas)

- Pheochromocytomas

- Gastrinomas (Zollinger-Ellison syndrome)

- Multiple endocrine neoplasia (MEN type I/II),

- Adrenal carcinomas with NET markers by immunohistochemistry (IHC) or serum

- Somatostatinoma

- VIPoma (vasoactive intestinal peptide)

- Merkel cell tumors

- Medullary thyroid carcinoma

- Neuroendocrine tumors of unknown primary site

- Patients must have progressed on octreotide therapy and/or radioactive isotopes linked to octreotide or its congeners if they had a positive octreotide scan; patients who have negative or mildly positive octreotide scans are exempt from this requirement

- Somatostatin analogs can be continued at their tolerated dose in patients with functional symptoms related to underlying disease such as in functional islet cell, insulinomas, glucagonomas etc

- Patients may have received prior chemotherapy for advanced disease including either capecitabine or temozolomide single agent as long as it did not include combination of capecitabine and temozolomide

- Patients must have completed prior (non-excluded) anti-cancer therapy (including surgery or chemotherapy or hepatic embolization/chemoembolization or radioactive isotopes i.e. yttrium 90) at least 4 weeks prior to day 1

- Patients with no brain metastases or a history of previously treated brain metastases who have been treated by surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of active intracranial disease and have not had treatment with steroids within 1 week of study enrollment

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Anticipated life expectancy of greater than 3 months

- Patients must have measurable disease either primary and/or metastatic masses reproducibly measurable in one or two diameters by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 parameters by CT scan or MRI scan; positron emission tomography (PET) or octreotide scans are useful adjuncts but will not be used to measure response

- Granulocytes > 1,500/ml

- Platelets > 100,000/ml

- Hemoglobin >= 10 g/dl

- Creatinine < 1.5 x upper limit of normal (ULN) or creatinine clearance >= 50 mL/min/1.73 m^2 for subjects with creatinine levels above institutional normal

- Bilirubin < 1.5 x ULN

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if liver metastases are present)

- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of veliparib, capecitabine and temozolomide administration

- Ability to understand and the willingness to sign a written informed consent document

- Patients must be able to swallow pills

Exclusion Criteria:

- Prior chemotherapy with combination of capecitabine (or 5-flourouracil [5-FU]) "and" temozolomide (or dacarbazine [DTIC]) will be excluded; patients can have had prior therapies up to 3 prior chemotherapy regimens such as streptozocin, anthracyclines, irinotecan, etoposide, or a platinum agent including single agent capecitabine (or 5FU) or temozolomide (or DTIC).

- History of severe hypersensitivity reaction to capecitabine, 5-FU, temozolomide or DTIC will be excluded (i.e. anaphylaxis or anaphylactoid reactions)

- Patients who have active or uncontrolled infection or serious medical or psychiatric illness preventing informed consent or on intensive treatment

- Patients with brain metastases are excluded

- Patients with uncontrolled seizures or any neurological conditions resulting in increased risk for seizures are not eligible for study entry

- Patients with documented central nervous system (CNS) ischemia and/or infarction, whether symptomatic or discovered incidentally without clinical symptoms, will be excluded from study participation

- Patients with a history of the arterial or venous thromboembolism within =< 12 months of study entry are not eligible

- Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are excluded from the study

- Patients with another active malignancy within the past five years except for carcinoma in situ of cervix or in situ carcinoma of the bladder or non-melanomatous carcinoma of the skin

- Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities

- Patients who are receiving any other investigational agents

- Major surgical procedure within 4 weeks of treatment

- Patients may not have any clinically significant cardiovascular disease including the following:

- Myocardial infarction or ventricular tachyarrhythmia within 6 months

- Prolonged QTc > 480 msec at baseline

- Symptomatic congestive heart failure (CHF) of New York Heart Association (NYHA) functional class >= 3

- Major conduction abnormality (unless a cardiac pacemaker is present)

- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with capecitabine or temozolomide or veliparib

Study Design


Related Conditions & MeSH terms

  • Adrenocortical Carcinoma
  • Carcinoid Tumor
  • Carcinoma
  • Carcinoma, Merkel Cell
  • Carcinoma, Neuroendocrine
  • Endocrine Gland Neoplasms
  • Functional Pancreatic Neuroendocrine Tumor
  • Gastrinoma
  • Glucagonoma
  • Insulinoma
  • Malignant Somatostatinoma
  • Merkel Cell Carcinoma
  • Metastatic Adrenal Gland Pheochromocytoma
  • Metastatic Carcinoid Tumor
  • Multiple Endocrine Neoplasia
  • Multiple Endocrine Neoplasia Type 1
  • Multiple Endocrine Neoplasia Type 2A
  • Multiple Endocrine Neoplasia Type 2B
  • Neoplasms
  • Neuroendocrine Neoplasm
  • Neuroendocrine Tumors
  • Non-Functional Pancreatic Neuroendocrine Tumor
  • Pancreatic Glucagonoma
  • Pancreatic Insulinoma
  • Pancreatic Neoplasms
  • Pheochromocytoma
  • Recurrent Adrenal Cortex Carcinoma
  • Recurrent Adrenal Gland Pheochromocytoma
  • Recurrent Merkel Cell Carcinoma
  • Somatostatin-Producing Neuroendocrine Tumor
  • Somatostatinoma
  • Stage III Adrenal Cortex Carcinoma
  • Stage III Thyroid Gland Medullary Carcinoma
  • Stage IIIA Merkel Cell Carcinoma
  • Stage IIIB Merkel Cell Carcinoma
  • Stage IV Adrenal Cortex Carcinoma
  • Stage IV Merkel Cell Carcinoma
  • Stage IVA Thyroid Gland Medullary Carcinoma
  • Stage IVB Thyroid Gland Medullary Carcinoma
  • Stage IVC Thyroid Gland Medullary Carcinoma
  • Thymic Carcinoid Tumor
  • Thyroid Diseases
  • Thyroid Neoplasms
  • VIP-Producing Neuroendocrine Tumor
  • Vipoma
  • Well Differentiated Adrenal Cortex Carcinoma
  • Zollinger Ellison Syndrome
  • Zollinger-Ellison Syndrome

Intervention

Drug:
Capecitabine
Given PO
Temozolomide
Given PI
Veliparib
given PO
Other:
Pharmacological Study
Correlative studies
Laboratory Biomarker Analysis
Correlative studies

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 Up to 28 days
Secondary Response rate measured as complete response, partial response or stable disease according to RECIST 1.1 criteria 56 days (2 courses)
Secondary Response duration Up to 4 weeks
Secondary Progression Free Survival From start of treatment to time of progression or death, assessed up to 4 weeks
Secondary Overall Survival Up to 4 weeks
Secondary Poly-adenosine diphosphate (ADP)-ribosylated (PAR) level Baseline to day 15 of course 1
See also
  Status Clinical Trial Phase
Recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Active, not recruiting NCT02978625 - Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Not yet recruiting NCT04705389 - SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines N/A
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Recruiting NCT05429866 - Immunological Variables Associated to ICI Toxicity in Cancer Patients Phase 2
Completed NCT04393753 - Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 Phase 2
Completed NCT03545334 - Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study N/A
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Recruiting NCT04291885 - Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma Phase 2
Terminated NCT02054884 - F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Phase 2
Recruiting NCT04975152 - Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Phase 1
Not yet recruiting NCT06039033 - Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns
Completed NCT02514824 - MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Phase 1/Phase 2
Recruiting NCT06056895 - Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma Phase 2
Recruiting NCT03370861 - How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Suspended NCT04916002 - A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer Phase 2
Recruiting NCT03210935 - French National Database of Rare Dermatological Cancers
Active, not recruiting NCT04116320 - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Phase 1
Not yet recruiting NCT06086288 - Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) Phase 2